Navigation Links
Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
Date:5/20/2010

SAN FRANCISCO and WASHINGTON, May 20 /PRNewswire/ -- Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today reported positive results from its Phase 1 dose escalation study evaluating the intravenous (IV) administration of JX-594 to patients with metastatic cancer.  The data presented today demonstrated clear dose-related delivery to solid tumors, cancer-targeted replication and gene expression, and anti-cancer effects of JX-594 delivered IV.  Choi (necrotic) responses were more commonly observed in patients treated at higher doses.  In addition, intravenous infusion of JX-594 was safe and well-tolerated.  These data were presented today at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Washington DC.

"These data represent a significant milestone for the field of oncology and viral therapy as this is the first time that a viral or genetic product has demonstrated reproducible, biopsy-proven delivery to multiple solid tumor types following intravenous administration," said David H. Kirn, M.D., president and chief executive officer of Jennerex.  "We look forward to extending our experience with IV JX-594 in our planned Phase 3 trial in patients with advanced liver cancer.  This pivotal trial will utilize both IV and targeted intratumoral injections of JX-594 to maximize potential patient benefit.  We expect to initiate this study in Q4 of 2010."

"JX-594 represents a promising potential treatment option for patients with multiple types of cancer.  As the first intravenous biological immunotherapy to demonstrate safety and tumor-specific delivery, JX-594 may add significantly to the armamentarium for many solid tumors," stated '/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... iLab Solutions announced the results of its ... on core facility operations, growth and utilization as well ... In its 4th year running, a number of long-term ... decrease in the percentage of revenue that comes from ... constraints of this trend. When asked, “What are your ...
(Date:9/30/2014)... LONDON , Sept. 30, 2014 ... analyze global next-generation (NGS) sequencing trends and use. ... technology use is expected to increase within the ... are the top criteria for purchasing sequencing instruments. ... technologies. The popularity of RNA-Seq continues to surge, ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 The custom ... ISPE Boston Product Show 2014. The Boston Area Chapter ... the 23rd annual, day-long event for Wed., Oct. 1 ... promises to be the largest in ISPE Boston’s long ... upward of 3,000 attendees expected. , HOLLOWAY AMERICA ...
(Date:9/30/2014)... Lyme Research Alliance (LRA), ... research at universities, today announced the awarding of seven ... treatment and cure for Lyme and other tick-borne diseases. ... applications in its history—over 20 grant proposals—a 100 percent ... pleased to receive so many solid applications from talented ...
Breaking Biology Technology:iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3Global Next-generation Sequencing Trends 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4
... , SOUTH BURLINGTON, Vt ., June 22 As previously ... Property including the patents of the Del-ID system to an Ontario ... is now pleased to announce leadership changes and appointments to QTECH,s Management Team ... of Kitchener, Ontario . , ...
... ... , ... Forza Silicon Corporation announced today that it is in a joint development effort with a ... CMOS image sensors., , , , ,Forza Silicon Corporation Chief Technology Officer, Daniel Van Blerkom, ...
... Researchers at Rensselaer Polytechnic Institute have developed a simple ... nanomaterial graphene. The new technique works at room temperature, ... mass production of graphene. An atom-thick sheet ... unique mechanical and electrical properties and is considered a ...
Cached Biology Technology:delSECUR CORPORATION Announces Organizational Update as QTECH SYSTEMS INC. Expands Leadership Team 2delSECUR CORPORATION Announces Organizational Update as QTECH SYSTEMS INC. Expands Leadership Team 3Forza Silicon Announces High Dynamic Range CMOS Sensor Development 2Researchers at Rensselaer Polytechnic Institute develop new method for mass-producing graphene 2Researchers at Rensselaer Polytechnic Institute develop new method for mass-producing graphene 3
(Date:9/30/2014)... KONG , Sept. 30, 2014 Winners of ... Economist Events, Innovation Summit scheduled to take place at the JW ... the summit, the award winners will share their experiences and the ... who have made a proven innovation over the past decade, will ... the night before the summit. It will be the first ...
(Date:9/29/2014)... , coupled with a high-fat diet, may cause animals to ... mBio , the online open-access journal of the American Society ... Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal observed that mice ... weight when fed a high-fat diet. Mice that did not ... consuming a high-fat diet, and mice that had C. ...
(Date:9/29/2014)... confirms that the exposure to tar tended to be ... cigarettes. Similarly, exposure to nicotine tended to be ... of cigarette in several countries around the world. Previous ... chemicals in the smoke of these cigarettes are lower ... of chemicals in the smoke are not necessarily linked ...
Breaking Biology News(10 mins):Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Gut bacteria promote obesity in mice 2Slim cigarette smokers not exposed to more harmful chemicals 2
... valves, can drive experimental samples through a lab-on-a-chip in ... This development could significantly simplify the process of conducting ... research will be published online in the Proceedings ... of July 20. A lab-on-a-chip, or microfluidic ...
... Mice with a defective mitochondrial protein called MCLK1 ... should spell disaster, yet according to a study in ... slower rate and live longer than normal mice. ... aging process; over time, reactive oxygen species produced by ...
... Malaria Research Institute have for the first time produced ... quantity to generate a significant immune response in mice ... vaccine. Antibodies induced by Pfs48/45 protein vaccine effectively blocked ... , as it grows within the mosquito. Sexual development ...
Cached Biology News:Music is the engine of new U-M lab-on-a-chip device 2Vaccine blocks malaria transmission in lab experiments 2
Bethyl Laboratories Ready-To-Use IHC Bluing Reagent is used following IHC hematoxylin counterstaining with immunohistochemical procedures. Shelf-Life: 1 year from date of receipt...
... 3F10B10. Immunogen: Synthetic peptide ... of JAB1 (Jun activation domain-binding ... Specific for the JAB1 protein. ... 293T Jurkat cell lysates). ...
ready-to-use solution...
...
Biology Products: